GlassScriptPhysician profile
Joseph A Larakers
NPI 1023057270
$13,356.32
in general payments reported to CMS, 2019-2025
42 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,073 · 2020: $2,021 · 2021: $2,415 · 2022: $2,046 · 2023: $1,769 · 2024: $1,712 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,800.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,214.16 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,783.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $978.37 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $880.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $841.98 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $669.81 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $629.91 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Janssen Pharmaceuticals, INC | $551.62 | 2019-2024 | Xarelto |
| Amgen INC. | $529.03 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $464.88 | 2019-2022 | |
| Pfizer INC. | $449.49 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $372.08 | 2019-2023 | Seglentis, Livalo |
| Takeda Pharmaceuticals U.S.A., INC. | $361.59 | 2019-2025 | Trintellix |
| Abbvie INC. | $312.86 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $269.78 | 2019-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Larakers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.